Billion to One

Billion to One

BillionToOne is a molecular diagnostics company with a mission to make molecular diagnostics more accurate, efficient, and accessible for all. The company's QCT molecular counter platform is the only technology that can count DNA molecules at the single-count level with single base-pair precision.
Products

Recently updated

Non-Invasive Prenatal Test (NIPT)
UNITY Screen

UNITY Screen is the only commercially available non-invasive prenatal test (NIPT) that assesses fetal risk for aneuploidies, recessive conditions, and fetal antigens from a maternal blood draw at 10+ weeks into pregnancy. It is able to quantify the tiny DNA changes floating in cell-free DNA using the company’s molecular counting technology. UNITY does not require a paternal blood sample to assess fetal risk, supporting more equitable care and enabling more pregnancies at risk to be affected with recessive conditions to be identified early in pregnancy as compared to traditional carrier screening.
More details

Tumor Burden Liquid Biopsy Test
Northstar Response (RUO)

The Northstar Response is a liquid biopsy test that provides longitudinal determination of cancer burden via methylation assessment. It determines multi cancer methylation signature (nucleotides are methylated in specific locations in cancers) and enables quantification of changes in tumor burden using the company’s molecular counting technology. The Northstar Response liquid biopsy test is currently available for research use only.
More details

Tumor Mutation Liquid Biopsy Test
Northstar Select (RUO)

The Northstar Select is a liquid biopsy test that provides a prioritized list of mutations, including deletions, insertions, and point-mutations, present in the tumor. At the same time, it helps rule-in/rule-out relationship of mutations to drugs and provides an accurate read on the covered genes. The Northstar Select liquid biopsy test is currently available for research use only.
More details

Clinical Laboratory

Non-Invasive Prenatal Test (NIPT)
UNITY Screen

UNITY Screen is the only commercially available non-invasive prenatal test (NIPT) that assesses fetal risk for aneuploidies, recessive conditions, and fetal antigens from a maternal blood draw at 10+ weeks into pregnancy. It is able to quantify the tiny DNA changes floating in cell-free DNA using the company’s molecular counting technology. UNITY does not require a paternal blood sample to assess fetal risk, supporting more equitable care and enabling more pregnancies at risk to be affected with recessive conditions to be identified early in pregnancy as compared to traditional carrier screening.
More details

Tumor Burden Liquid Biopsy Test
Northstar Response (RUO)

The Northstar Response is a liquid biopsy test that provides longitudinal determination of cancer burden via methylation assessment. It determines multi cancer methylation signature (nucleotides are methylated in specific locations in cancers) and enables quantification of changes in tumor burden using the company’s molecular counting technology. The Northstar Response liquid biopsy test is currently available for research use only.
More details

Tumor Mutation Liquid Biopsy Test
Northstar Select (RUO)

The Northstar Select is a liquid biopsy test that provides a prioritized list of mutations, including deletions, insertions, and point-mutations, present in the tumor. At the same time, it helps rule-in/rule-out relationship of mutations to drugs and provides an accurate read on the covered genes. The Northstar Select liquid biopsy test is currently available for research use only.
More details
Copyright © 2000-2026 TradeMed.com. All rights reserved. | Terms And Conditions